Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Viktoria Blumenberg, Benjamin Puliafito, Charlotte Graham, Mark B. Leick, Md. Raihan Chowdhury, Maxx King, Deshea L Harris, Noopur Raje, Andrew R. Branagan, Andrew J. Yee, Diana Cirstea, Kathleen Gallagher, Jörg Dietrich, Marcela V. Maus, Matthew J. Frigault
Abstract
ABSTRACT: Potentially fatal non-immune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy have been linked to high CAR T-cell expansion. Cyclophosphamide to ablate CAR T cells is an effective strategy to mitigate steroid-refractory NINTs.
Topics & Concepts
CyclophosphamideMedicineCAR T-cell therapyPersistence (discontinuity)Internal medicineChemotherapyEngineeringCancerImmunotherapyChimeric antigen receptorGeotechnical engineeringCAR-T cell therapy researchNanowire Synthesis and ApplicationsIntegrated Circuits and Semiconductor Failure Analysis